| Patent application number | Description | Published |
|---|
| 20100184758 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS - Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety. | 07-22-2010 |
| 20100286123 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL - This invention relates to compounds having structural Formula I: | 11-11-2010 |
| 20110201615 | TRIAZOLE BETA CARBOLINE DERIVATIVES AS ANTI-DIABETIC AGENTS - Beta-carboline derivatives of structural formula (I) are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety. | 08-18-2011 |
| 20130217680 | Inhibitors of the Renal Outer Medullary Potassium Channel - This invention relates to compounds having structural Formula (I); and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir 1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure. | 08-22-2013 |
| 20130225561 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL - This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure. | 08-29-2013 |
| 20140031349 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL - The present invention provides compounds of Formula I | 01-30-2014 |
| 20140142115 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL - This invention relates to compounds having structural Formula I: | 05-22-2014 |
| 20140206618 | Inhibitors of the Renal Outer Medullary Potassium Channel - The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention. | 07-24-2014 |
| 20140235628 | Inhibitors of the Renal Outer Medullary Potassium Channel - This invention relates to compounds having structural Formula I: | 08-21-2014 |
| 20140275020 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL - This invention relates to compounds of Formula I having the following general structure: | 09-18-2014 |
| 20140288042 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL - This invention relates to compounds of Formula I having the following general structure: | 09-25-2014 |
| 20140296225 | Inhibitors of the Renal Outer Medullary Potassium Channel - The present invention provides compounds of Formula I | 10-02-2014 |
| 20140309213 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL - This invention relates to compounds of Formula I-VI having the following general structure: | 10-16-2014 |
| 20140336177 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL - The present invention provides compounds of Formula I | 11-13-2014 |
| 20150099729 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL - The present invention provides compounds of Formula I | 04-09-2015 |
| 20150299198 | Inhibitors of the Renal Outer Medullary Potassium Channel - The present invention provides compounds of Formula I | 10-22-2015 |
| 20150329557 | Inhibitors of the Renal Outer Medullary Potassium Channel - The present invention provides compounds of Formula I | 11-19-2015 |
| 20160002259 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL - The present invention provides compounds of Formula I | 01-07-2016 |
| Patent application number | Description | Published |
|---|
| 20080267314 | Digital microwave radio system and method with encryption - A communications system are provided that provides integrated encryption capabilities. In particular, a digital microwave system, terminal and method are provided in which the encryption functions are integrated into the digital microwave terminals. The digital microwave system may also be implemented with external encryption units. | 10-30-2008 |
| 20110081872 | Digital Microwave Radio Link with a Variety of Ports - A microwave radio terminal capable of multiple gigabits/sec bit rate is provided. The radio terminal may use QAM modulation, including the two lowest modulation formats of BPSK and QPSK. The serial bit stream, including forward error correction (FEC) and all other overhead, is prepared in a digital circuit, such as a filed programmable gate array (FPGA) and is output serially, using SERDES devices inside the FPGA, as two separate channels known as “I-channel” and “Q-channel”. | 04-07-2011 |
| 20120154239 | MILLIMETER WAVE RADIO ASSEMBLY WITH A COMPACT ANTENNA - An integrated compact antenna device and method of aiming an electromagnetic signal using the integrated compact antenna device are described. The integrated compact antenna device be a vertically mounted cylinder enclosing an antenna, some electronic circuitry and most of the directional alignment mechanism. During alignment, the cylinder of the ICA rotates to provide azimuth. The cylinder is attached to a fixed base that remains stationary relative to the mounting structure. | 06-21-2012 |
| 20140049123 | HIGHLY RELIABLE ACTUATOR WITH MULTIPLE DEGREES OF FREEDOM AND METHOD FOR MOVING A PAYLOAD USING THE ACTUATOR - An actuator that has two or more degrees of freedom that moves a payload are described. The actuator may have two members, an actuator stator and an actuator armature, with the ability to move relative to each other in two or more degrees of freedom. | 02-20-2014 |
| Patent application number | Description | Published |
|---|
| 20080261893 | TOPICAL CORNEAL ANALGESIA USING NEUROTENSIN RECEPTOR AGONISTS AND SYNERGISTIC NEUROTENSIN COMBINATIONS WITHOUT DELAYING WOUND HEALING - A method for administering an ocular analgesic is described. The method includes the steps of providing a topical analgesic that includes a neo-tryptophan-containing neurotensin analog and applying the topical analgesic to the ocular tissue in a dose of about 0.0001 to about 5 mg alternatively about 0.0001 to about 3 mg, alternatively about 0.0005 to about 1.2 mg, alternatively about 0.0005 to about 1.0 mg, alternatively about 0.00075 to about 1.0 mg, alternatively about 0.001 mg to about 1.0 mg, alternatively about 0.001 mg to about 0.8 mg, alternatively about 0.001 mg to about 0.7 mg, alternatively about 0.001 mg to about 0.6 mg. Methods of administering a topical analgesic containing a neo-tryptophan-containing neurotensin analog are also described. The topical analgesic can be administered in a patch, gel, lotion, spray, or mist. | 10-23-2008 |
| 20120207789 | TOPICAL CORNEAL ANALGESIA USING NEUROTENSIN RECEPTOR AGONISTS AND SYNERGISTIC NEUROTENSIN COMBINATIONS WITHOUT DELAYING WOUND HEALING - Ocular analgesics for topical administration are described. The topical ocular analgesic includes a neo-tryptophan-containing neurotensin analog. The topical ocular analgesic may alternatively include a buffered salt solution, a local anesthetic solution, a tissue penetrating agent, and/or an opiate. The neo-tryptophan-containing neurotensin analog may be present in a dose of about 0.0005 to about 1.2 mg. | 08-16-2012 |
| 20120208766 | TOPICAL CORNEAL ANALGESIA USING NEUROTENSIN RECEPTOR AGONISTS AND SYNERGISTIC NEUROTENSIN COMBINATIONS WITHOUT DELAYING WOUND HEALING - A method for administering an ocular analgesic is described. The method includes the steps of providing a topical analgesic that includes a neo-tryptophan-containing neurotensin analog and applying the topical analgesic to the ocular tissue in a dose of about 0.0001 to about 5 mg, alternatively about 0.0001 to about 3 mg, alternatively about 0.0005 to about 1.2 mg, alternatively about 0.0005 to about 1.0 mg, alternatively about 0.00075 to about 1.0 mg, alternatively about 0.001 mg to about 1.0 mg, alternatively about 0.001 mg to about 0.8 mg, alternatively about 0.001 mg to about 0.7 mg, alternatively about 0.001 mg to about 0.6 mg. Methods of administering a topical analgesic containing a neo-tryptophan-containing neurotensin analog are also described. The topical analgesic can be administered in a patch, gel, lotion, spray, or mist. | 08-16-2012 |
| 20150080314 | TOPICAL CORNEAL ANALGESIA USING NEUROTENSIN RECEPTOR AGONISTS AND SYNERGISTIC NEUROTENSIN COMBINATIONS WITHOUT DELAYING WOUND HEALING - Ocular analgesics for topical administration are described. The topical ocular analgesic includes a neo-tryptophan-containing neurotensin analog. The topical ocular analgesic may alternatively include a buffered salt solution, a local anesthetic solution, a tissue penetrating agent, and/or an opiate. The neo-tryptophan-containing neurotensin analog may be present in a dose of about 0.0005 to about 1.2 mg. | 03-19-2015 |
| 20150273011 | TOPICAL CORNEAL ANALGESIA USING NEUROTENSIN RECEPTOR AGONISTS AND SYNERGISTIC NEUROTENSIN COMBINATIONS WITHOUT DELAYING WOUND HEALING - A method for administering an ocular analgesic is described. The method includes the steps of providing a topical analgesic that includes a neo-tryptophan-containing neurotensin analog and applying the topical analgesic to the ocular tissue in a dose of about 0.0001 to about 5 mg, alternatively about 0.0001 to about 3 mg, alternatively about 0.0005 to about 1.2 mg, alternatively about 0.0005 to about 1.0 mg, alternatively about 0.00075 to about 1.0 mg, alternatively about 0.001 mg to about 1.0 mg, alternatively about 0.001 mg to about 0.8 mg, alternatively about 0.001 mg to about 0.7 mg, alternatively about 0.001 mg to about 0.6 mg. Methods of administering a topical analgesic containing a neo-tryptophan-containing neurotensin analog are also described. The topical analgesic can be administered in a patch, gel, lotion, spray, or mist. | 10-01-2015 |
| Patent application number | Description | Published |
|---|
| 20130042366 | HERBICIDE-TOLERANT PLANTS - The present invention provides saflufenacil-tolerant plants. The present invention also provides methods for controlling the growth of weeds by applying saflufenacil to which the saflufenacil-tolerant plants of the invention are tolerant. Plants of the invention express a cytochrome P450 polypeptide, the expression of which confers, to the plants, tolerance to the saflufenacil. | 02-14-2013 |
| 20140173776 | Herbicide-Metabolizing Cytochrome P450 Monooxygenases - The present invention refers to method for producing a transgenic plant with increased herbicide tolerance or resistance as compared to a corresponding non-transformed wild type plant, comprising transforming a plant cell or a plant cell nucleus or a plant tissue with a nucleic acid molecule encoding an | 06-19-2014 |
| 20150087519 | Substituted N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamide compounds and their use as herbicides - N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamides of formula I and their use as herbicides, | 03-26-2015 |
| 20150111750 | Substituted N-(tetrazol-5-yl)- and N-(triazol-5-yl)hetarylcarboxamide compounds and their use as herbicides - N-(tetrazol-5-yl)- and N-(triazol-5-yl)hetarylcarboxamides of formula I and their use as herbicides. | 04-23-2015 |
| 20150119249 | Substituted N-(tetrazol-5-yl)- and N-(triazol-5-yl)pyridin-3-yl-carboxamide compounds and their use as herbicides - N-(tetrazol-5-yl)- and N-(triazol-5-yl)pyridin-3-yl-carboxamides of formula I and their use as herbicides, formula I. The invention relates to N-(tetrazol-5-yl)- and N-(triazol-5-yl)pyridin-3-yl-carboxamides of formula I and their use as herbicides. In said formula I, B represents N or CH, whereas R, R | 04-30-2015 |
| 20150181879 | Substituted pyridine compounds having herbicidal activity - The present invention provides a substituted pyridine compound of the formula I | 07-02-2015 |
| 20150291570 | Substituted N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamide compounds and their use as herbicides - N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamides of formula I and their use as herbicides. | 10-15-2015 |
| 20150322453 | HERBICIDE-METABOLIZING CYTOCHROME P450 MONOOXYGENASES - The present invention refers to method for producing a transgenic plant with increased herbicide tolerance or resistance as compared to a corresponding non-transformed wild type plant, comprising transforming a plant cell or a plant cell nucleus or a plant tissue with a nucleic acid molecule encoding an | 11-12-2015 |
| Patent application number | Description | Published |
|---|
| 20110296382 | Mechanism for Dynamic Software Testing Using Test Entity - A mechanism for performing dynamic software testing on a computer system using a test entity. A method of embodiments of the invention includes causing a test execution script to run a test based on a first configuration setting as defined in the test execution script. The test execution script is executed in a script execution environment utilizing a software framework of a computer system. The method further includes modifying, in runtime, the first configuration setting into a second configuration setting, and causing, in runtime, the test execution script to rerun the test based on the second configuration setting. | 12-01-2011 |
| 20110296383 | Mechanism for Performing Dynamic Software Testing Based on Test Result Information Retrieved in Runtime Using Test Result Entity - A mechanism for performing dynamic software testing on a computer system based on test result information retrieved in runtime using test result entity. A method of embodiments of the invention includes causing a test execution script to run a first test to test a first component, and the test execution script is supported by a script execution platform on a computer system, and the first component depends on a second component. The method further includes retrieving, in runtime, testing information relating to the second component from a database, if the first test produces unsatisfactory results relating to performance of the first component, and causing, in runtime, the test execution script to run a second test to test the second component. | 12-01-2011 |
| 20110296384 | Mechanism for Performing Dynamic Software Testing Based on Grouping of Tests Using Test List Entity - A mechanism for performing dynamic software testing on a computer system based on grouping of tests using a test list entity. A method of embodiments of the invention includes causing execution a first group of first tests based on a first set of configuration settings, and executing the first group includes enabling a test execution script to run the first tests according to the first set of configuration settings, and the test execution script is hosted at a test execution platform of a computer system. The method further includes facilitating creation, in runtime, a second group of second tests based on a second set of configuration settings that is different from the first set of configuration settings, and causing execution, in runtime, the second group of second tests, and executing the second group includes enabling the test execution script to run the second tests according to the second set of configuration settings. | 12-01-2011 |
| 20110314243 | METHOD AND APPARATUS FOR RESTRICTING ACCESS TO WRITABLE PROPERTIES AT RUNTIME - A processing device executing an application receives a user command to update a specified writeable property of the application. The processing device determines whether the specified writeable property has metadata that distinguishes the specified writeable property as a user updateable property. In one embodiment, this is determined by using a reflection mechanism to examine metadata of the specified writeable property. In another embodiment, this is determined by examining a dynamic changeable properties list that was created and populated at runtime of the application. If the specified writeable property has the metadata that distinguishes the specified writeable property as a user updateable property, the processing device updates the specified writeable property in accordance with the user command. | 12-22-2011 |
| 20120084413 | Mechanism for Installing Monitoring Utilities Using Universal Performance Monitor - A universal performance monitor includes an abstraction layer for managing multiple disparate monitoring tools on one or more computing devices. During runtime of the universal performance monitor on a first computing device, the universal performance monitor establishes a secure channel between the first computing device and a second computing device. The universal performance monitor queries the second computing device via the secure channel to determine whether the second computing device includes a specified monitoring tool. Upon determining that the second computing device does not include the specified monitoring tool, the universal performance monitor causes the second computing device to obtain the specified monitoring tool from a designated location, to install the specified monitoring tool with a particular configuration, to execute the specified monitoring tool and to redirect an output of the specified monitoring tool to the first computing device via the first secure channel. | 04-05-2012 |
| 20120084608 | Mechanism for Performing Verification of Template Integrity of Monitoring Templates Used for Customized Monitoring of System Activities - A mechanism for performing verification of template integrity of monitoring templates used for customized monitoring of system activities. A method of embodiments of the invention includes calculating a first hash code for a monitoring template, the monitoring template to customize a performance monitor to serve as a universal monitor to facilitate a plurality of monitoring tools to perform monitoring of activities of a plurality of system components of the computer system, extracting the first hash code from the monitoring template, and calculating a second hash code for the monitoring template. The method further includes verifying integrity of the monitoring template by comparing the first hash code with the second hash code, and the integrity of the monitoring template is determined to be satisfactory if the first hash code matches the second hash code. | 04-05-2012 |
| 20120096527 | POWERSHELL CMDLETS CODE GENERATING TOOL FOR COMMUNICATING TO THE WEB SERVICES - An objected oriented shell code generating tool receives data that identifies a Web service hosted by a server. The tool creates proxy code to generate a Web service client proxy to identify a plurality of methods for the Web service. For each method, the tool automatically creates object driven shell commands code that defines a class implementing parameters of the Web service method, wherein the object driven shell commands code is to be executed in an object driven shell platform to communicate with the Web service method via the client proxy. The tool generates invocation infrastructure code for communicating to the Web service method via the client proxy and deploys the proxy code, the invocation infrastructure code, and the object driven shell commands code in the object driven shell platform on the client to call a Web service method via the invocation infrastructure and the client proxy. | 04-19-2012 |
| 20120210299 | Method And Apparatus for Generating Persistent Variables In A Shell Environment - A computing device executes one or more applications within a shell session, such as a Powershell session. The computing device may detect, within the shell session, a runtime exception that causes the shell session to prematurely terminate. The computer device serializes an object associated with the runtime exception prior to closure of the shell session. The computer device may also serialize other objects. Serializing the object includes identifying the object's type, identifying data associated with the object's type, identifying internal types of the object, and identifying data associated with each of the internal types, and generating a representation of the object that preserves the object's type, the data included in the object, and all internal types of the object. | 08-16-2012 |
| 20140115017 | RESTFUL SERVICE DESCRIPTION LANGUAGE - A processing device identifies uniform resource identifiers (URIs) for a RESTful (Representational State Transfer) web service in a server and creates server-side metadata describing each of the URIs without nesting metadata of one of the URIs in metadata of another one of the URIs. The processing device creates a file that includes the URIs and the corresponding server-side metadata for the corresponding URI to describe the RESTful web service. | 04-24-2014 |
| 20140156828 | METHOD AND SYSTEM FOR ABSTRACTING RESTFUL WEB SERVICE HTTP BETWEEN A CLIENT AND A SERVER - A computer system identifies metadata components that are associated with uniform resource identifiers (URIs) in service description language metadata for a RESTful (Representational State Transfer) web service The computer system identifies a programming language for a template pertaining to a method of a software development kit (SDK) client. The computer system creates the template. The template includes programming code placeholders for the metadata components based on the identified programming language. | 06-05-2014 |
| 20140157227 | METHOD AND SYSTEM FOR PRESERVING RESTFUL WEB SERVICE STRUCTURE IN A CLIENT CONSUMING THE RESTFUL WEB SERVICE - A computer system identifies a uniform resource identifier (URI) that corresponds to a resource of a RESTful web service. The URI contains elements. The computer system identifies a relationship between the elements of the URI and creates programming code for a method of a software development kit (SDK) client. The method reflects the relationships between the elements of the URI to facilitate communication with the resource of the RESTful web service. | 06-05-2014 |
| 20140157228 | METHOD AND SYSTEM FOR AUTOMATICALLY GENERATING A RESTFUL WEB SERVICE SOFTWARE DEVELOPMENT KIT CLIENT - A computer system receives user input indicating uniform resource identifiers (URIs) for a RESTful web service. The computer system identifies a programming language for a RESTful web service software development kit (SDK) client and creates methods for the URIs using programming code format of the identified programming language. The computer system creates the RESTful web service SDK client using the methods. | 06-05-2014 |
